Ask HopeStage to review this study with me
Study ID: NCT01626833. We help you review the study, but cannot decide medical eligibility.
CompletedNCT01626833
Severe Decrease of Growth Velocity in Children With Eating disorders.Therapeutic study of Growth Hormone
This study is completed. It focuses on eating disorders and currently lists study information in France.
Eating disorders, Interruption of Growth, ...DrugFrom 8 Years to 203 Months
Key information made simple
What is this study testing?
This study is testing whether Growth Hormone Severe Decrease of Growth Velocity may be useful for children experiencing eating disorders.
What would participation involve?
Participants may receive Growth Hormone Severe Decrease of Growth Velocity, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in France.
Who is it mainly for?
This study appears to be mainly for children with eating disorders. Because it involves minors, a parent or guardian may need to be involved.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.
Your next step
The official record does not clearly describe the visit format, so the practical details are best checked directly in the source. Participation appears to involve study activities and follow-up chosen by the research team. The main fit and exclusions are best confirmed in the eligibility section of the official record. The phase details are not clearly stated here.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: March 2013
- Recruitment status
- Completed
- Estimated enrollment
- Not clearly listed
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- France
- Age range
- From 8 Years to 203 Months
- Official registry ID
- NCT01626833
- Official title
- Severe Decrease of Growth Velocity in Children With Anorexia Nervosa. Therapeutic Trial of Growth Hormone
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT01626833. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular follow-up, often through questionnaires or interviews.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with eating disorders. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.
Who might this study be for?
This study may concern people with eating disorders; age range: From 8 Years to 203 Months. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
Will I need to change, stop, or stabilize my current treatment?
The public registry appears to mention rules about current treatment, stability, stopping treatment, or dose changes. Do not change your treatment for a study without medical guidance. Ask the study team and your clinician what is required, what is not allowed, and how safety is monitored.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Assistance Publique - Hôpitaux de Paris, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is completed. It may still be useful for understanding the research, but you are unlikely to be able to join.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT00481975
Rimonabant on Weight Loss and Frequency of Binge Episodes for Eating disorders
This study is completed in the United States, in France, in Switzerland, .... It is testing rimonabant on Weight Loss and Frequency of Binge Episodes for Eating disorders.
CompletedNCT02524301
Evaluation of Brain Opioid Receptor Activity in Eating disorders : a PET [11C]Diprenorphine Study
This study is completed. It focuses on eating disorders and currently lists study information in France.
CompletedNCT02359513
Evaluation of the Efficacy of Serotoninergic Antidepressants in Eating disorders, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF.
This study is completed in France. It focuses on Eating disorders.